Skip to main content
PDSB
NASDAQ Life Sciences

PDS Biotechnology 公布2025年每股亏损74美分的重大损失

feedReported by Dow Jones Newswires
Sentiment info
Negative
Importance info
8
Price
$0.57
Mkt Cap
$29.626M
52W Low
$0.523
52W High
$1.915
Market data snapshot near publication time

summarizeSummary

PDS Biotechnology 已报告2025年全年每股亏损$0.74。这是一个高度重要的财务结果，尤其考虑到该公司当前的股票价格约为$0.57。每股亏损超过当前股票价格，表明公司存在显著的非盈利性，并可能引发人们对公司财务健康和未来可持续性的担忧。交易者需要立即评估这种巨大损失对公司估值和经营前景的影响。

在该公告发布时，PDSB的交易价格为$0.57，交易所为NASDAQ，所属行业为Life Sciences，市值约为$2962.6万。 52周交易区间为$0.52至$1.92。 这则新闻被评估为消极市场情绪，重要性评分为8/10。 来源：Dow Jones Newswires。

show_chartPrice Chart

Share this article

Copied!

feed PDSB - Latest Insights

PDSB
Apr 27, 2026, 11:51 AM EDT
Filing Type: S-3/A
Importance Score:
9
PDS Biotech Files $200M Universal Shelf Registration Following Positive Phase 2 Data
Sentiment: Negative
View Wiseek Article
PDSB
Apr 15, 2026, 8:45 AM EDT
Source: GlobeNewswire
Importance Score:
9
PDS01ADC Shows 78% ORR, >80% 2-Year Survival in mCRC Phase 2 Trial, Data Published
Sentiment: Positive
View Wiseek Article
PDSB
Mar 30, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
9
PDS Biotech Amends Phase 3 Trial for Accelerated Approval Pathway, Reports Encouraging Clinical Data
Sentiment: Positive
View Wiseek Article
PDSB
Mar 30, 2026, 7:02 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
PDS Biotechnology Reports Significant 74-Cent Per Share Loss for 2025
Sentiment: Negative
View Wiseek Article
PDSB
Mar 03, 2026, 12:03 PM EST
Source: Wiseek News
Importance Score:
8
PDS Biotechnology Receives Nasdaq Deficiency Notice for Minimum Bid Price
Sentiment: Negative
View Wiseek Article
PDSB
Mar 03, 2026, 12:01 PM EST
Filing Type: 8-K
Importance Score:
9
PDS Biotechnology Receives Nasdaq Delisting Notice for Minimum Bid Price Non-Compliance
Sentiment: Negative
View Wiseek Article
PDSB
Feb 20, 2026, 8:35 AM EST
Filing Type: 8-K
Importance Score:
8
PDS Biotech Adopts Amended Phase 3 Protocol for Accelerated Approval Pathway of PDS0101
Sentiment: Positive
View Wiseek Article
PDSB
Jan 28, 2026, 8:50 AM EST
Filing Type: 8-K
Importance Score:
8
PDS Biotech's PDS01ADC Shows Promising Phase 2 Results in Advanced Prostate Cancer
Sentiment: Positive
View Wiseek Article
PDSB
Jan 22, 2026, 8:50 AM EST
Filing Type: 8-K
Importance Score:
8
PDS Biotech Secures Key U.S. Patent for Lead Cancer Immunotherapy PDS0101, Extending Market Protection
Sentiment: Positive
View Wiseek Article
PDSB
Jan 09, 2026, 8:50 AM EST
Filing Type: 8-K
Importance Score:
8
PDS Biotech Submits Phase 3 Protocol Amendment for Accelerated PDS0101 Approval Pathway
Sentiment: Positive
View Wiseek Article